Condition: Superficial Basal Cell Carcinoma · Nodular Basal Cell Carcinoma · Sponsor: MediWound Ltd
This study will be a multicenter, prospective, open label, one-arm study intended to assess the Safety and Efficacy of EscharEx (EX-02) in the treatment of Basal Cell Carcinoma. In patients with one primary superficial or nodular basal cell carcinoma lesion with a diameter of 5-10mm (Histologically confirmed BCC) located on the trunk or upper extremities (not including the hands), with well-defined borders and no previous radiation therapy.
This description comes directly from the study's public registry record.
Limor Dinur Klein, PhD · 972779714000 · limord@mediwound.com
Keren David, MSc · kerend@mediwound.com
Always discuss trial participation with your own doctor first.
| Center for Clinical and Cosmetic Research | Aventura, Florida, United States | Recruiting |
| Moore Clinical Research, Inc. | Brandon, Florida, United States | Not Yet Recruiting |
| Center for Clinical Studies, LTD. LLP | Webster, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05157763